CRISPR Therapeutics (CRSP) Competitors $71.30 -1.77 (-2.42%) As of 11:11 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CRSP vs. ALLO, AXSM, BEAM, EDIT, KALA, MRNA, NTLA, VRTX, BNTX, and TEVAShould you be buying CRISPR Therapeutics stock or one of its competitors? The main competitors of CRISPR Therapeutics include Allogene Therapeutics (ALLO), Axsome Therapeutics (AXSM), Beam Therapeutics (BEAM), Editas Medicine (EDIT), KALA BIO (KALA), Moderna (MRNA), Intellia Therapeutics (NTLA), Vertex Pharmaceuticals (VRTX), BioNTech (BNTX), and Teva Pharmaceutical Industries (TEVA). These companies are all part of the "medical" sector. CRISPR Therapeutics vs. Its Competitors Allogene Therapeutics Axsome Therapeutics Beam Therapeutics Editas Medicine KALA BIO Moderna Intellia Therapeutics Vertex Pharmaceuticals BioNTech Teva Pharmaceutical Industries CRISPR Therapeutics (NASDAQ:CRSP) and Allogene Therapeutics (NASDAQ:ALLO) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, risk, profitability, institutional ownership, media sentiment, earnings and dividends. Is CRSP or ALLO more profitable? Allogene Therapeutics has a net margin of 0.00% compared to CRISPR Therapeutics' net margin of -1,229.43%. CRISPR Therapeutics' return on equity of -20.05% beat Allogene Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets CRISPR Therapeutics-1,229.43% -20.05% -17.09% Allogene Therapeutics N/A -55.99%-42.75% Do analysts rate CRSP or ALLO? CRISPR Therapeutics currently has a consensus price target of $71.71, suggesting a potential upside of 0.57%. Allogene Therapeutics has a consensus price target of $8.44, suggesting a potential upside of 567.55%. Given Allogene Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Allogene Therapeutics is more favorable than CRISPR Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CRISPR Therapeutics 2 Sell rating(s) 7 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.42Allogene Therapeutics 2 Sell rating(s) 2 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.54 Which has more volatility and risk, CRSP or ALLO? CRISPR Therapeutics has a beta of 1.84, indicating that its share price is 84% more volatile than the S&P 500. Comparatively, Allogene Therapeutics has a beta of 0.43, indicating that its share price is 57% less volatile than the S&P 500. Does the media favor CRSP or ALLO? In the previous week, CRISPR Therapeutics had 8 more articles in the media than Allogene Therapeutics. MarketBeat recorded 16 mentions for CRISPR Therapeutics and 8 mentions for Allogene Therapeutics. CRISPR Therapeutics' average media sentiment score of 0.88 beat Allogene Therapeutics' score of 0.33 indicating that CRISPR Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CRISPR Therapeutics 5 Very Positive mention(s) 4 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Allogene Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Which has higher valuation & earnings, CRSP or ALLO? Allogene Therapeutics has lower revenue, but higher earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Allogene Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCRISPR Therapeutics$35M185.28-$366.25M-$5.43-13.13Allogene TherapeuticsN/AN/A-$257.59M-$1.11-1.14 Do institutionals & insiders hold more shares of CRSP or ALLO? 69.2% of CRISPR Therapeutics shares are owned by institutional investors. Comparatively, 83.6% of Allogene Therapeutics shares are owned by institutional investors. 4.3% of CRISPR Therapeutics shares are owned by insiders. Comparatively, 13.2% of Allogene Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. SummaryAllogene Therapeutics beats CRISPR Therapeutics on 8 of the 15 factors compared between the two stocks. Get CRISPR Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CRSP and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CRSP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRSP vs. The Competition Export to ExcelMetricCRISPR TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.46B$3.34B$6.06B$10.38BDividend YieldN/A2.31%5.73%4.78%P/E Ratio-13.0722.1986.0626.86Price / Sales185.28415.96582.90180.66Price / CashN/A44.9825.7330.17Price / Book3.1510.3012.686.63Net Income-$366.25M-$52.31M$3.31B$276.12M7 Day Performance1.58%0.15%-0.66%-1.86%1 Month Performance26.73%13.31%8.45%5.63%1 Year Performance52.19%27.02%77.27%32.94% CRISPR Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRSPCRISPR Therapeutics1.7122 of 5 stars$71.30-2.4%$71.71+0.6%+56.0%$6.46B$35M-13.07460Analyst ForecastGap UpALLOAllogene Therapeutics2.5349 of 5 stars$1.39+4.1%$8.44+509.7%-53.6%$307.30M$20K-1.25310News CoverageAnalyst ForecastGap UpAXSMAxsome Therapeutics4.6683 of 5 stars$119.68-0.5%$177.93+48.7%+39.0%$5.97B$385.69M-23.60380Analyst RevisionBEAMBeam Therapeutics3.073 of 5 stars$25.95+0.8%$46.40+78.8%+6.5%$2.64B$63.52M-5.79510Analyst ForecastEDITEditas Medicine4.2313 of 5 stars$3.86-1.7%$5.10+32.3%+16.6%$348.44M$32.31M-1.36230KALAKALA BIO4.0585 of 5 stars$1.54flat$20.38+1,223.1%-72.9%$10.71M$3.89M-0.2230High Trading VolumeMRNAModerna4.221 of 5 stars$27.70-2.8%$41.81+50.9%-54.0%$10.77B$3.24B-3.685,800Analyst ForecastNTLAIntellia Therapeutics3.8652 of 5 stars$20.58+3.1%$27.95+35.8%+32.0%$2.21B$57.88M-4.38600VRTXVertex Pharmaceuticals4.7789 of 5 stars$403.240.0%$493.81+22.5%-15.3%$103.37B$11.02B28.826,100Positive NewsAnalyst ForecastAnalyst RevisionBNTXBioNTech2.1411 of 5 stars$105.19-0.3%$134.56+27.9%-15.3%$25.28B$2.98B-65.726,772Analyst ForecastTEVATeva Pharmaceutical Industries3.2284 of 5 stars$19.91-0.5%$25.57+28.5%+16.0%$22.85B$16.54B-124.5336,830Analyst Upgrade Related Companies and Tools Related Companies Allogene Therapeutics Alternatives Axsome Therapeutics Alternatives Beam Therapeutics Alternatives Editas Medicine Alternatives KALA BIO Alternatives Moderna Alternatives Intellia Therapeutics Alternatives Vertex Pharmaceuticals Alternatives BioNTech Alternatives Teva Pharmaceutical Industries Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CRSP) was last updated on 10/13/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CRISPR Therapeutics AG Please log in to your account or sign up in order to add this asset to your watchlist. Share CRISPR Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
